Press Releases

U.S. Patent and Trademark Office Terminates Interference Proceeding in Favor of PDL BioPharma, Inc. INCLINE VILLAGE, Nev., Dec. 20, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on December 15, 2010 , the U.S.

PDL BioPharma Provides Fourth Quarter 2010 Revenue Guidance of $74 Million INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2010 of approximately $74 million, as

PDL BioPharma Announces Third Quarter 2010 Financial Results INCLINE VILLAGE, Nev., Nov. 10, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the third quarter and nine months ended September 30, 2010.

PDL BioPharma Completes Exchange to Retire $92.0 Million of 2.00% Convertible Notes Due August 2012 INCLINE VILLAGE, Nev., Nov. 5, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the exchange of $92.0 million in aggregate principal of

PDL BioPharma to Announce Third Quarter 2010 Financial Results on November 10, 2010 INCLINE VILLAGE, Nev., Nov. 2, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that the Company will release its third quarter financial results on Wednesday, November 10,

PDL BioPharma to Present at Oppenheimer and Lazard Capital Markets Annual Healthcare Conferences INCLINE VILLAGE, Nev., Oct 28, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that management is scheduled to present at the following upcoming investor

PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012 INCLINE VILLAGE, Nev., Oct 27, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL, the Company) (Nasdaq: PDLI) today announced that it has entered into separate privately negotiated exchange

PDL BioPharma Completes October 1 Special Dividend Payment INCLINE VILLAGE, Nev., Oct 04, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has paid the October 1, 2010 special dividend payment of $0.50 per share to all stockholders owning shares of

PDL BioPharma Announces Retirement of $54.3 Million of 2.75% Convertible Notes Due 2023 INCLINE VILLAGE, Nev., Sept 16, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the retirement of the remaining $54.3 million in aggregate principal

PDL BioPharma to Present at Upcoming Investor Conferences INCLINE VILLAGE, Nev., Sept 15, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the following upcoming

PDL BioPharma Announces Conversion Rate Adjustment for 2.00% Convertible Senior Notes Due February 15, 2012 INCLINE VILLAGE, Nev., Sept 13, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior

PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes INCLINE VILLAGE, Nev., Sept 10, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) affirmed that on September 15, 2010 it will redeem all of the Company's outstanding 2.75%

PDL BioPharma Announces Ex-Dividend Date of September 13 for Special Dividend INCLINE VILLAGE, Nev., Sept 09, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that NASDAQ has established September 13, 2010 as the ex-dividend date for its second of two special

PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech INCLINE VILLAGE, Nev., Sept 01, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter

PDL BioPharma Receives Letter from Genentech Relating to European Patents INCLINE VILLAGE, Nev., Aug 13, 2010 /PRNewswire via COMTEX/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today it has received a facsimile letter from Genentech asserting that Avastin ® , Herceptin ® , Lucentis ® and